




Identify Partners Series

# NEUROLOGY STARTUPS

A Comprehensive Report  
on Identifying New Connections

# 2020



World's Largest Resource on **Top 370**  
NEUROLOGY DRUG DEVELOPERS

- STARTUPS PROFILES
- RESEARCH PIPELINE
- MAJOR DEALS
- CURRENT FUNDING STATUS



**OmicsX**  
innovation INSIGHTS

Drug Discovery **Startups**

***IDENTIFY PARTNERS SERIES -***

# **NEUROLOGY STARTUPS 2020**

**WORLD'S LARGEST RESOURCE ON NEUROLOGY DRUG DEVELOPING STARTUPS**

**QUANTITATIVE & QUALITATIVE ANALYSIS OF TOP 370 STARTUPS ESTABLISHED BETWEEN 2010-2019**



<i>Executive Summary</i> .....	4
<i>List of Figures</i> .....	8
<i>List of Tables</i> .....	8
<i>List of Top 370 Neurology Startups</i> .....	9

## **Section A : Neurology Startups 2020 - Top 370 Active Drug Developer's Summary** **13**

- *Infographics - Quantitative Estimation of Neurology Startups present in U.S.A vs. Europe vs. Asia vs. Canada vs. Rest of the World (established between 2010 to 2019).* **14**
- *Infographics - Distribution of Top 370 Neurology Startups, on the basis of Year of Establishment.* **14**  
To explore the emergence of Neurology Drug Discovery And Development.
- *Infographics - Country-wise Distribution of Neurology Startups having Active Neurology Drug Development Program in Europe and Asia Region.* **15**  
To identify best and emerging countries, for promoting neurology startups.
- *Infographics - State-wise Distribution of Neurology Startups having Active Neurology Drug Development Program in U.S.A.* **15**  
To explore the Top neurology startups supporting States in United States.
- *Intelligence - Top 20 Innovative Game Changer Neurology Startups.* **16**  
Capable of changing tomorrow's Neurology Drug Discovery & Development.

□ <i>Intelligence - Stem Cell Therapy Developing Neurology Startups.</i> (15 Startups)	<b>18</b>
□ <i>Intelligence - Gene Therapy Developing Neurology Startups.</i> (21 Startups)	<b>19</b>
□ <i>Drugs in Development by Neuro Startups - Alzheimer's Disease.</i> (76 Startups)	<b>20</b>
□ <i>Drugs in Development by Neuro Startups - Parkinson Disease.</i> (70 Startups)	<b>23</b>
□ <i>Drugs in Development by Neuro Startups - Pain Treatment.</i> (41 Startups)	<b>26</b>
□ <i>Drugs in Development by Neuro Startups - Multiple Sclerosis.</i> (32 Startups)	<b>29</b>
□ <i>Drugs in Development by Neuro Startups - Epilepsy.</i> (26 Startups)	<b>30</b>
□ <i>Drugs in Development by Neuro Startups - Ischemic Stroke &amp; Traumatic Brain Injury.</i> (26 Startups)	<b>31</b>
□ <i>Drugs in Development by Neuro Startups - Schizophrenia.</i> (14 Startups)	<b>32</b>

## **Section B : Neurology Startups 2020 - Funding , Deals & Partnering Activities **33****

□ <i>Neurology Startups - Major Deals &amp; Partnering Activities in 2019.</i> (uptill Sep. 2019)	<b>34</b>
□ <i>Neurology Startups - Major Deals &amp; Partnering Activities in 2018.</i> (37 Deals)	<b>36</b>
□ <i>Neurology Startups - Major Deals &amp; Partnering Activities in 2017.</i> (30 Deals)	<b>39</b>
□ <i>Neurology Startups - Venture Funding - 2019.</i> Including Seed Funding, Equity Funding with Series Round A/B/C/D details; IPO; Debt Funding and Grants	<b>42</b>
□ <i>Neurology Startups - Venture Funding - 2018</i> (75 Records) Including Seed Funding, Equity Funding with Series Round A/B/C/D details; IPO; Debt Funding and Grants	<b>44</b>
□ <i>Neurology Startups - Venture Funding - 2017</i> (47 Records) Including Seed Funding, Equity Funding with Series Round A/B/C/D details; IPO; Debt Funding and Grants	<b>48</b>
□ <i>Key Venture Capital Investors in Neurology Startups and their Investment Portfolio.</i> Atlas Ventures, Roche Venture Fund, Lilly Ventures, Third Rock Ventures and Avlon Ventures.	<b>50</b>
□ <i>Intelligence - Key Neurology Startups supported by The Michael J. Fox Foundation for Parkinson's Research.</i>	<b>52</b>

## Section C : Neurology Startups 2020 -Company Profile (with Active Pipeline)

**53**

### □ *A to Z Alphabetical Profiles of Active Neurology Startup Companies (370 Companies)*

Individual company Pages includes: **Company Profile**, Key technology platform, Venture Funding Rounds, Neurology centered Deals & Partnership, Collaborations and Business Insights.

**Neurology Drug Pipeline** –Drugs name, its targets, with details of its development for various indications for cancer cure, FDA/EMA Orphan drug status.

**Management Profile** –Address, Contact number, e-mail, Key Management / Decision Maker (CXOs) name and designation, with individual Linked ID and contact emails.

*Appendix A: Country Wise List of 370 Neurology Startup Companies.....* **291**

*Appendix B: Complete 448 Molecules List, along with their Developer's Name.....* **294**

## List of Figures:

### Section A : Neurology Drug Developer Startups - *Infographics*

<b>Figure A.1</b>	Qualitative Estimation of Top 370 Active Neurology Startups, established between 2010-2019; present in <b>U.S.A vs. Europe vs. Asia vs. Rest of the World.</b>	14
<b>Figure A.2</b>	Bar Graph for Yearwise Establishment of Top 370 Active Neurology Startups; between 2010 to 2019.	14
<b>Figure A.3</b>	Individual Country-wise Distribution of Top 370 Neurology Startups (Drug Developer) in EuroAsia Region - <b>Europe</b> (82 Startups in 15 Countries) and in <b>Asia</b> (23 Startups in 6 Countries).	15
<b>Figure A.4</b>	State-wise Distribution of Neurology Startups in <b>U.S.A.</b> (established between 2010 - 2019).	15

## List of Tables:



### Section A : Neurology Drug Developer Startups - *Intelligence*

<b>Table A.1</b>	<i>Intelligence</i> - Top 20 <b>Highly Innovative Startups</b> capable of changing future of Neurology Drug Discovery & Development.	16
<b>Table A.2</b>	Stem Cell targeting Neurology Startups & their Technologies (15 Companies).	18
<b>Table A.3</b>	Gene Therapy focused Neurology Startups & their Technologies (21 Companies).	19
<b>Table A.4</b>	<i>Research Pipeline</i> - <b>Alzheimer's Disease</b> - Developer Name, Molecule, Target & Developmental Stage.	20
<b>Table A.5</b>	<i>Research Pipeline</i> - <b>Parkinson Disease</b> - Developer Name, Molecule, Target & Developmental Stage.	23
<b>Table A.6</b>	<i>Research Pipeline</i> - <b>Pain Disease</b> - Developer Name, Molecule, Target & Developmental Stage.	26
<b>Table A.7</b>	<i>Research Pipeline</i> - <b>Amyotrophic Lateral Sclerosis</b> - Developer Name, Molecule, Target & Developmental Stage.	28
<b>Table A.8</b>	<i>Research Pipeline</i> - <b>Multiple Sclerosis</b> - Developer Name, Molecule, Target & Developmental Stage.	29
<b>Table A.9</b>	<i>Research Pipeline</i> - <b>Epilepsy</b> - Developer Name, Molecule, Target & Developmental Stage.	30
<b>Table A.10</b>	<i>Research Pipeline</i> - <b>Ischemic Stroke &amp; Traumatic Brain Injury</b> - Developer Name, Molecule, Target & Developmental Stage.	31
<b>Table A.11</b>	<i>Research Pipeline</i> - <b>Schizophrenia</b> - Developer Name, Molecule, Target & Developmental Stage.	32
<b>Table B.1</b>	<i>Intelligence</i> - Neurology Startups Major Deals & Partnering Activities - 2019	34
<b>Table B.2</b>	<i>Intelligence</i> - Neurology Startups Major Deals & Partnering Activities - 2018	36
<b>Table B.3</b>	<i>Intelligence</i> - Neurology Startups Major Deals & Partnering Activities - 2017	39
<b>Table B.4</b>	<i>Intelligence</i> - Neurology Startups Funding - 2019	42
<b>Table B.5</b>	<i>Intelligence</i> - Neurology Startups Funding - 2018	44
<b>Table B.6</b>	<i>Intelligence</i> - Neurology Startups Funding - 2017	48
<b>Table B.7</b>	Top 5 Venture Investors in Neurology Startups and Their Investment Portfolio - Atlas Ventures.	50
<b>Table B.8</b>	Top 5 Venture Investors in Neurology Startups and Their Investment Portfolio - Roche Venture Fund.	50
<b>Table B.9</b>	Top 5 Venture Investors in Neurology Startups and Their Investment Portfolio - Lilly Ventures.	50
<b>Table B.10</b>	Top 5 Venture Investors in Neurology Startups and Their Investment Portfolio - Third Rock Ventures.	51
<b>Table A.11</b>	Top 5 Venture Investors in Neurology Startups and Their Investment Portfolio - Avlon Ventures.	51
<b>Table A.12</b>	Key Neurology Startups supported by The Michael J. Fox Foundation for Parkinson's Research.	52

# Section A

**WORLDWIDE DISTRIBUTION OF NEUROLOGY STARTUPS**  
**DISTRIBUTION OF NEUROLOGY STARTUPS IN EURO-ASIA**  
**TOP 20 INNOVATIVE STARTUPS IN NEUROLOGY DRUG DISCOVERY**  
**STEM CELL THERAPY DEVELOPING NEUROLOGY STARTUPS**  
**GENE THERAPY DEVELOPING NEUROLOGY STARTUPS**  
**DRUGS IN DEVELOPMENT BY NEURO STARTUPS - ALZHEIMER'S DISEASE**  
**DRUGS IN DEVELOPMENT BY NEURO STARTUPS - PARKINSON'S DISEASE**  
**DRUGS IN DEVELOPMENT BY NEURO STARTUPS - PAIN**  
**DRUGS IN DEVELOPMENT BY NEURO STARTUPS - ALS**  
**DRUGS IN DEVELOPMENT BY NEURO STARTUPS - MULTIPLE SCLEROSIS**  
**DRUGS IN DEVELOPMENT BY NEURO STARTUPS - EPILEPSY DISEASE**  
**DRUGS IN DEVELOPMENT BY NEURO STARTUPS - STROKE DISEASE**  
**DRUGS IN DEVELOPMENT BY NEURO STARTUPS - SCHIZOPHRENIA DISEASE**

## INFOGRAPHICS- COUNTRY WISE DISTRIBUTION OF COMPANIES IN EUROPE & ASIA





## Intelligence - STEM CELL THERAPY DEVELOPING NEUROLOGY STARTUPS (15 Companies)

Table No. A.2

	COMPANY NAME	DESCRIPTION
1.	<b>BlueRock Therapeutics LP</b> <i>Canada</i>	BlueRock is developing unique CELL+GENE™ platform to direct cellular differentiation and genetically engineer cells to create an entirely new generation of cellular medicines in the areas of neurology, cardiology, and immunology. Its platform is based on induced pluripotent stem cells (iPSCs), which can be generated from cells in a normal blood draw from a consenting adult, and replace dead, damaged, or dysfunctional cells in patients with degenerative disease.
6.	<b>Healios K.K.</b> <i>Japan</i>	Healios K.K. (formerly Retina Institute Japan K.K.) is a biotech venture company leading the field of developing iPS cell-based products for regenerative medicine and is developing a product for treatment of age-related macular degeneration jointly with Suimitomo Dainippon Pharma.
12.	<b>Talisman Therapeutics</b> <i>United Kingdom</i>	Talisman's novel human stem cell models of AD provide a transformative platform for rapid and relevant compound identification, which significantly accelerate drug discovery. Talisman's is utilizing it, to identify novel pharmacological treatments for Alzheimer's disease, through in-house drug discovery programme.
14.	<b>TreeFrog Therapeutics</b> <i>France</i>	TreeFrog has developed C-Stem™, its proprietary technology for stem cell culture; a 3D cell culture system enabling the mass production of stem cells with short lead times, while preserving genomic integrity. Treefrog grows the stem cells in a 3D clump inside tiny capsules made from alginate, a component in seaweed. The alginate capsules protect the stem cells from mechanical stresses in the bioreactor while letting nutrients pass into the capsules. Furthermore, the capsules can also protect the cells while being transported between different sites.

## Intelligence - GENE THERAPY DEVELOPING NEUROLOGY STARTUPS (21 companies)

Table No. A.3

	COMPANY NAME	DESCRIPTION
1		
2		
3		
4		
5	<b>DegenRx B.V.</b> <i>Netherlands</i>	DegenRx is developing single domain heavy chain shark antibody, a so-called VNAR*, which are much smaller than conventional antibodies. By using AAV-mediated gene therapy the gene encoding for the antibody is delivered directly into the brain, thus making the neurons express the antibody where it is needed without having to pass the BBB.
6		
7		
8		
9		
10		
11		
12	<b>Neurogene Inc.</b> <i>U.S.A.</i>	Neurogene is developing AAV-based gene therapy technology to deliver a normal gene to patients having a dysfunctional genes.
13		
14		
15		
16		
17		
18		
19	<b>SwanBio Therapeutics Inc.</b> <i>U.S.A.</i>	SwanBio Therapeutics, is developing AAV (adeno-associated virus) based gene therapies for treating neurological disease.
20		
21		

## Pipeline Analysis - DRUGS IN DEVELOPMENT BY NEURO STARTUPS TARGETING ALZHEIMER'S DISEASE (76 Companies / 81 Molecules)

Table No. A.4

	COMPANY NAME	COUNTRY	MOLECULE	TARGET	DEVP STAGE	MOLECULE TYPE
1.						
2.						
3.						
4.	Alzamend Neuro, Inc	U.S.A	Alzamend/ CAO22W	-	Preclinical	Vaccine
			Liprosal		Preclinical	Small molecule
5.						
6.						
7.						
8.						
9.						
10.						
11.						
12.						
13.						
14.						
15.						
16.						
17.	Athira Pharma inc	U.S.A	NDX-1017	HGF receptor	Phase I	Small Molecule
18.						
19.						
20.						
21.						
22.						
23.						
24.						
25.						
26.						
27.						
28.	Dermaxon LLC	U.S.A	DX0314	-	Preclinical	Small Molecule
29.						
30.						
31.						
32.						
33.	Gismo Therapeutics, Inc.	U.S.A	GTC-3000	-	Preclinical	Small Molecule
			GTC-6000	Tau	Preclinical	Small Molecule
34.						

## Pipeline Analysis - DRUGS IN DEVELOPMENT BY NEURO STARTUPS TARGETING PARKINSON'S DISEASE (70 Companies / 74 Molecules)

Table No. A.5

	COMPANY NAME	COUNTRY	MOLECULE	TARGET	DEVP STAGE	MOLECULE TYPE
1.	1st Biotherapeutics Inc.	South Korea	1 ST-102	cAbl	Preclinical	Small Molecule
2.						
3.						
4.						
5.						
6.						
7.						
8.	Athira Pharma inc	U.S.A	NDX-1017	HGF receptor	Preclinical	Small Molecule
9.						
10.						
11.						
12.						
13.						
14.						
15.						
16.						
17.						
18.	Cerevance LLC	U.S.A	CVN424	D2 Dopamine receptor	I	Small Molecule
			CNV417	-	Preclinical	Small Molecule
19.						
20.						
21.						
22.						
23.						
24.						
25.						
26.						
27.						
28.						
29.						
30.						
31.						
32.						
33.						
34.						
35.	Io Therapeutics, Inc.	U.S.A	IRX4204	Retinoid X Receptor	Phase I	Small Molecule

# Section B

**MAJOR DEALS & PARTNERING ACTIVITIES - 2019**

**MAJOR DEALS & PARTNERING ACTIVITIES - 2018**

**MAJOR DEALS & PARTNERING ACTIVITIES - 2017**

**VENTURE FUNDING 2019**

**VENTURE FUNDING 2018**

**VENTURE FUNDING 2017**

**BIG PHARMA INVESTMENTS & DEALS**

**TOP 5 VENTURE INVESTORS**

## Intelligence - NEUROLOGY STARTUPS MAJOR DEALS & PARTNERING ACTIVITIES - 2019

Table No. B.1

NO	COMPANY NAME	MONTH	PARTNER	SHORT DESCRIPTION
1	1st Biotherapeutics, Inc.	Jan-19	twoXAR Inc.	1st Biotherapeutics and twoXAR Inc., an artificial intelligence (AI)-driven biopharma company, signed an agreement to jointly discover and develop novel, efficacious treatments for glioblastoma multiforme. Under the terms, twoXAR, to identify drug candidates against glioblastoma, using its proprietary AI technology. Following identification of one or more candidates based on the evaluation, 1st Biotherapeutics will further optimize candidates. Further details remains undisclosed.
2				
3				
4				
5				
6				
7	Recursion Pharmaceuticals, LLC	Jan-19	Ohio State University	Recursion entered into licensing agreement with the Ohio State University, gaining exclusive worldwide rights to develop and commercialize a clinical-stage compound OSU-HDAC42, now REC-2282, against neurofibromatosis type 2 (NF2), a devastating rare tumor syndrome.
8				
9				
10				
11	Arvelle Therapeutics GmbH	Feb-19	SK Biopharmaceuticals	Arvelle Therapeutics and SK Biopharmaceuticals entered into an exclusive licensing agreement to develop and commercialize a small molecule Cenobamate in Europe, which is an investigational antiepileptic drug for treatment of partial-onset seizures in adult patients. Under the terms, SK Biopharmaceuticals received an upfront payment of \$100 Mn and is eligible to receive up to \$430 Mn upon achievement of certain regulatory and commercial milestones in addition to royalties on net sales generated in Europe.
12				
13				
14				
15				
16				
17				
18	Abide Therapeutics, LLC	May-19	H. Lundbeck A/S	Lundbeck has agreed to acquire Abide Therapeutics for \$250 Mn upfront. Lundbeck could pay Abide shareholders up to another \$150 Mn if the company's drugs hit certain development and sales milestones.

## Intelligence - NEUROLOGY STARTUPS FUNDING - 2019

Table No. B.4

No	STARTUP NAME	MONTH	FUNDING TYPE	SHORT DESCRIPTION
1	Arvelle Therapeutics GmbH	Jan-19	Seed Funding	Arvelle Therapeutics received one of the largest initial financing commitments for a European-focused biopharmaceutical company from a global syndicate of investors that include NovaQuest, LSP, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners.
2				
3				
4				
5				
6				
7				
8				
9	Falcon Therapeutics Inc.	Mar-19	Grant	Falcon was awarded with nearly \$1,500,000 Phase II Small Business Technology Transfer (SBTT) grant from the National Institutes of Health (NIH) to deliver life-saving therapies to patients fighting Glioblastoma (GBM).
10				
11				
12				
13				
14				
15				
16	GliaCure, Inc.	Apr-19	Series C	GliaCure raised over \$11 Mn in Seed C financing round from private investors and charitable foundations such as ADDE.
17				
18				
19				
20				
21				
22				
23				
24	DegenRx B.V.	Jun-19	Grant	DegenRx B.V. and Center for Neurogenomics & Cognitive Research (CNCR) were awarded a grant from the Top Sector Life Sciences & Health (Health~Holland) for their joint research program on antibody-based gene therapy for the treatment of Alzheimer's disease (AD).

370

**NEUROLOGY STARTUPS PROFILES**

**Section C**